These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 38722986)
1. Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme. Bourner J; Redji Mbrenga FD; Malaka CN; Dunning J; Rojek A; Fandema E; Horby P; Boum Y; Nakouné E; Olliaro P PLoS One; 2024; 19(5):e0278957. PubMed ID: 38722986 [TBL] [Abstract][Full Text] [Related]
2. Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022-2023. Yu PA; Elmor R; Muhammad K; Yu YC; Rao AK NEJM Evid; 2024 Oct; 3(10):EVIDoa2400189. PubMed ID: 39270215 [TBL] [Abstract][Full Text] [Related]
3. Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024. Gigante CM; Takakuwa J; McGrath D; Kling C; Smith TG; Peng M; Wilkins K; Garrigues JM; Holly T; Barbian H; Kittner A; Haydel D; Ortega E; Richardson G; Hand J; Hacker JK; Espinosa A; Haw M; Kath C; Bielby M; Short K; Johnson K; De La Cruz N; Davidson W; Hughes C; Green NM; Baird N; Rao AK; Hutson CL MMWR Morb Mortal Wkly Rep; 2024 Oct; 73(40):903-905. PubMed ID: 39388389 [TBL] [Abstract][Full Text] [Related]
4. Monkeypox: A re-emerging disease. Kaur N; Dabar J; Bassi P Indian J Pharmacol; 2024 Mar; 56(2):129-135. PubMed ID: 38687317 [TBL] [Abstract][Full Text] [Related]
5. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus. DeLaurentis CE; Kiser J; Zucker J Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026 [TBL] [Abstract][Full Text] [Related]
8. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948 [TBL] [Abstract][Full Text] [Related]
9. Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox. Suzuki T; Saito S; Tsuzuki S; Ashida S; Takakusaki M; Yoshikawa T; Shimojima M; Ebihara H; Ohmagari N; Morioka S BMJ Open; 2023 Aug; 13(8):e069550. PubMed ID: 37527886 [TBL] [Abstract][Full Text] [Related]
10. Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques. Russo AT; Grosenbach DW; Brasel TL; Baker RO; Cawthon AG; Reynolds E; Bailey T; Kuehl PJ; Sugita V; Agans K; Hruby DE J Infect Dis; 2018 Sep; 218(9):1490-1499. PubMed ID: 29982575 [TBL] [Abstract][Full Text] [Related]
11. Tecovirimat for Monkeypox in Central African Republic under Expanded Access. Mbrenga F; Nakouné E; Malaka C; Bourner J; Dunning J; Vernet G; Horby P; Olliaro P N Engl J Med; 2022 Dec; 387(24):2294-2295. PubMed ID: 36449745 [No Abstract] [Full Text] [Related]
12. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022. O'Laughlin K; Tobolowsky FA; Elmor R; Overton R; O'Connor SM; Damon IK; Petersen BW; Rao AK; Chatham-Stephens K; Yu P; Yu Y; MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1190-1195. PubMed ID: 36107794 [TBL] [Abstract][Full Text] [Related]
13. Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection. Desai AN; Thompson GR; Neumeister SM; Arutyunova AM; Trigg K; Cohen SH JAMA; 2022 Oct; 328(13):1348-1350. PubMed ID: 35994281 [TBL] [Abstract][Full Text] [Related]
14. Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat. Hernandez LE; Jadoo A; Kirsner RS Lancet; 2022 Sep; 400(10355):e8. PubMed ID: 36088950 [No Abstract] [Full Text] [Related]
15. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Berhanu A; Prigge JT; Silvera PM; Honeychurch KM; Hruby DE; Grosenbach DW Antimicrob Agents Chemother; 2015 Jul; 59(7):4296-300. PubMed ID: 25896687 [TBL] [Abstract][Full Text] [Related]
16. Successful Distribution of Tecovirimat During the Peak of the Mpox Outbreak - Los Angeles County, June 2022-January 2023. O'Neil MJ; Archer R; Danza P; Fisher R; Bagwell DA; Younis I; Kulkarni S; Rubin Z; Kim M; Balter S; Terashita D; Kim J; Singhal R; Hancz D; Gausche-Hill M; Shah NK MMWR Morb Mortal Wkly Rep; 2024 Jun; 73(24):546-550. PubMed ID: 38900699 [TBL] [Abstract][Full Text] [Related]
17. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. Shamim MA; Padhi BK; Satapathy P; Veeramachaneni SD; Chatterjee C; Tripathy S; Akhtar N; Pradhan A; Dwivedi P; Mohanty A; Rodriguez-Morales AJ; Sah R; Al-Tammemi AB; Al-Tawfiq JA; Nowrouzi-Kia B; Chattu VK Int J Infect Dis; 2023 Feb; 127():150-161. PubMed ID: 36470502 [TBL] [Abstract][Full Text] [Related]
18. Repurposing existing drugs for monkeypox: applications of virtual screening methods. Li V; Lee Y; Lee C; Kim H Genes Genomics; 2023 Nov; 45(11):1347-1355. PubMed ID: 37713070 [TBL] [Abstract][Full Text] [Related]
19. Clinical considerations on monkeypox antiviral medications: An overview. Pourkarim F; Entezari-Maleki T Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674 [TBL] [Abstract][Full Text] [Related]
20. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023. Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]